YTHDF1 and non-small cell lung carcinoma: Additionally, Shi et al. have reported that the low expression of the m6A-binding protein factor YTHDF1 in the body can cause resistance to cisplatin therapy in non-small-cell carcinoma (NSCLC) patients, and the therapeutic effect is poor [30].